Mortality Number of deaths at maximum · participants with unresectable hepatocellular carcinoma
External beam radiotherapy (EBRT) plus transarterial… may leads to lower all‐cause mortality (at maximum 1‐year compared with TACE alone (low certainty).
1 finding from 1 review
All‐cause mortality: 1‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 1‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Interferon‐α alone probably leads to higher 1‐year mortality compared with standard targeted therapies (sunitinib or temsirolimus) (moderate certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Interferon‐α alone showed no clear difference in 1‐year mortality compared with interferon‐α plus bevacizumab (low certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Vaccine treatment showed no clear difference in 1‐year mortality compared with standard therapies (low certainty).
1 finding from 1 review
1‐year mortality · previously treated patients with mRCC
Targeted immunotherapy alone probably leads to lower 1‐year mortality compared with standard targeted therapies (moderate certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Interferon‐α combined with targeted therapies showed no clear difference in 1‐year mortality compared with standard targeted therapy (moderate certainty).
1 finding from 1 review
Death (all causes) · previously untreated patients with mRCC
Interferon‐α plus bevacizumab showed no clear difference in 1‐year mortality median compared with standard targeted therapies (low certainty).
1 finding from 1 review